Q-omics provides the consensus-scored SYT15 profile across patient tissues and cancer cell-line models. SYT15 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SYT15 is differentially expressed in 16, with the highest sampling consensus in KICH. Additionally, SYT15 RNA expression shows 17,210 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KICH, and UVM as cancer lineages where SYT15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYT15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYT15 survival associations across molecular data types. SYT15 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYT15 RNA expression–survival associations across cancer types. High SYT15 expression shows unfavorable associations in UCEC and KIRP, but favorable associations in BLCA, HNSC, LGG and SCLC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SYT15 RNA expression.
This table summarizes SYT15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SYT15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYT15 shows lower tumor expression in KICH, COAD, LUAD, UCEC, HNSC and LUSC. The KICH box plot shows higher SYT15 RNA expression in normal versus tumor tissue (log2 FC = −0.410, t-test p < 0.001).
This table shows molecular features associated with SYT15 in patient tissues and cancer cell lines. In patient samples, SYT15 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SYT15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
